Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
McKinsey
Dow
Colorcon

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR LURBINECTEDIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Lurbinectedin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01314599 ↗ Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome Completed PharmaMar Phase 1 2011-05-01 Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183.
NCT01831089 ↗ Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed PharmaMar Phase 1 2013-09-01 Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
NCT01951157 ↗ A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients Completed PharmaMar Phase 2 2013-09-11 A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lurbinectedin

Condition Name

Condition Name for Lurbinectedin
Intervention Trials
Advanced Solid Tumor 5
Advanced Solid Tumors 3
Small-cell Lung Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lurbinectedin
Intervention Trials
Lung Neoplasms 8
Neoplasms 7
Small Cell Lung Carcinoma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lurbinectedin

Trials by Country

Trials by Country for Lurbinectedin
Location Trials
United States 72
Spain 23
Italy 10
United Kingdom 6
Brazil 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lurbinectedin
Location Trials
Texas 7
Massachusetts 7
California 5
New York 5
Pennsylvania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lurbinectedin

Clinical Trial Phase

Clinical Trial Phase for Lurbinectedin
Clinical Trial Phase Trials
Phase 3 4
Phase 2 7
Phase 1/Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lurbinectedin
Clinical Trial Phase Trials
Completed 10
Not yet recruiting 8
Recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lurbinectedin

Sponsor Name

Sponsor Name for Lurbinectedin
Sponsor Trials
PharmaMar 17
Jazz Pharmaceuticals 5
National Cancer Institute (NCI) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lurbinectedin
Sponsor Trials
Industry 27
Other 11
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Merck
Johnson and Johnson
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.